1. Introduction Acute myeloid leukemia (AML) is the most prevalent form of leukemia in adults, comprising 80% of all adult leukemia cases [1]. The incidence of AML escalates with age, rising from 1.3 per million individuals under 65 years old to 12.2 per million in those over 65 years old [2,3]. Leukemia cells often display various mutations, for instance, the FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3/ITD) mutation is observed in 30% AML [4,5].